Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.

Health technology assessment (Winchester, England)

Volumn 14 Suppl 1, Issue , 2010, Pages 47-53

  Fleeman, N ^a   Bagust, A ^b   McLeod, C ^b   Greenhalgh, J ^b   Boland, A ^b   Dundar, Y ^b   Dickson, R ^b   Tudur Smith, C ^b   Davis, H ^b   Green, J ^b   Pearson, M ^b  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; CARBOPLATIN; CISPLATIN; DEOXYCYTIDINE; DOCETAXEL; DRUG DERIVATIVE; GEMCITABINE; GLUTAMIC ACID DERIVATIVE; GUANINE; IMMUNOSUPPRESSIVE AGENT; PEMETREXED; RADIOSENSITIZING AGENT; TAXOID;

COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; PATHOLOGY; QUALITY ADJUSTED LIFE YEAR; REVIEW; STATISTICAL MODEL; UNITED KINGDOM;

ANTIMETABOLITES, ANTINEOPLASTIC; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE PROGRESSION; GLUTAMATES; GREAT BRITAIN; GUANINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG NEOPLASMS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; RADIATION-SENSITIZING AGENTS; TAXOIDS;

EID: 84886942984     PISSN: None     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta14suppl1/07     Document Type: Review

References (33)